Clinical Trial

Reduced Dose Radiotherapy vs Standard Dose Radiotherapy for Early Stage Nasopharyngeal Carcinoma

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study investigates whether administering reduced dose is non-inferior to standard dose radiotherapy in terms of 3-year locoregional relapse-free survival (LRRFS) rate for stage I nasopharyngeal carcinoma patients who are sensitive to radiotherapy.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-03; most recent amendment 2025-04-16.
Status change: Not Yet Recruiting → Recruiting 2025-04-16
Trial Details
NCT Number NCT06912698
Lead Sponsor Hai-Qiang Mai,MD,PhD
Conditions Nasopharyngeal Cancinoma (NPC)
Enrollment 342 participants
Start Date 2025-05-22
Primary Completion 2031-04-19 (estimated)
Study Completion 2033-03-19 (estimated)
Updated on ClinicalTrials.gov 2025-04-22